Učitavanje...
Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models
The HER2 receptor is overexpressed in approximately 20% of breast cancers and is associated with tumorigenesis, metastasis, and a poor prognosis. Trastuzumab is a first-line targeted drug used against HER2(+) breast cancers; however, at least 50% of HER2(+) tumors develop resistance to trastuzumab....
Spremljeno u:
| Izdano u: | Sci Rep |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4828666/ https://ncbi.nlm.nih.gov/pubmed/27068794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep24298 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|